As shown in Fig. 5b, about 11, 26, and 10.5% of diffuse-type C-I, C-II, and intestinal-type GCs exhibited PIK3CA mutations in TCGA cohort, and the overall responsive rate was reported 35% for cancer patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors [51]. The gene discussed is MTOR; the disease is cancer.